Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Gynecology

Free Subscription Articles published in Oncogene Retrieve available abstracts of 55 articles: HTML format

Single Articles

June 2026
1. SUNDARARAJAN V, Ziyu F, Elfar GA, Tan TZ, et al
   Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition.
   Oncogene. 2026 Jun 11. doi: 10.1038/s41388-026-03830.
   PubMed     Abstract available
   
   
   
2. CHEN Y, Lu D, Xing Y, He J, et al
   The translation landscape of ovarian clear cell carcinoma indicates that RBM4 plays a pro-oncogenic role in tumor progression.
   Oncogene. 2026 Jun 5. doi: 10.1038/s41388-026-03840.
   PubMed     Abstract available
   
   
   May 2026
3. LI Y, Chen Z, Diao Y, Gao Q, et al
   SNRPD2-CPSF7-UBE2K axis drives ovarian cancer progression via alternative splicing-polyadenylation crosstalk.
   Oncogene. 2026 May 7. doi: 10.1038/s41388-026-03812.
   PubMed     Abstract available
   
   
   April 2026
4. WEI Y, Chen Z, Li Y, Song K, et al
   Correction: The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
   Oncogene. 2026 Apr 23. doi: 10.1038/s41388-026-03810.
   PubMed    
   
   
   
5. LOBERMEYER A, Schollhorn JS, Rademacher PN, Wankner MC, et al
   Pre-operative circulating tumor cells predict worse treatment outcome in patients with high-grade serous ovarian cancer.
   Oncogene. 2026 Apr 4. doi: 10.1038/s41388-026-03747.
   PubMed     Abstract available
   
   
   
6. PU Y, Chen Z, Gao Q, Liu Y, et al
   Spliceosomal component SNRPE drives cell proliferation by regulating CTP synthase 1 mRNA splicing in ovarian cancer.
   Oncogene. 2026 Apr 4. doi: 10.1038/s41388-026-03764.
   PubMed     Abstract available
   
   
   March 2026
7. PEI X, Wang F, Liu X, Lei Y, et al
   Core fucosylation of NCEH1 by FUT8 promotes progression of high-grade serous ovarian cancer by driving tumor-associated macrophage M2 polarization.
   Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03703.
   PubMed     Abstract available
   
   
   
8. WEBB JD, Buensuceso A, Tomas EJ, Borrelli MJ, et al
   ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer.
   Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03702.
   PubMed     Abstract available
   
   
   February 2026
9. CHENG G, Jiang W, Li Z, Ma Y, et al
   TFAP2C protects against ferroptosis in ovarian cancer through the KEAP1-NRF2 axis by recruiting HDAC1/2.
   Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03692.
   PubMed     Abstract available
   
   
   
10. XU J, Shi G, Qin Z, Yin B, et al
    Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling.
    Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03693.
    PubMed     Abstract available
    
    
    
11. VISWANADHAPALLI S, Lee TK, Elmore S, Sharma G, et al
    Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.
    Oncogene. 2026 Feb 6. doi: 10.1038/s41388-026-03689.
    PubMed     Abstract available
    
    
    January 2026
12. SUN J, Cai X, Yung MMH, Zhou W, et al
    Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2026 Jan 16. doi: 10.1038/s41388-026-03676.
    PubMed    
    
    
    December 2025
13. JI F, Yan K, Ding B, Zhu Y, et al
    Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.
    Oncogene. 2025 Dec 17. doi: 10.1038/s41388-025-03663.
    PubMed     Abstract available
    
    
    
14. LI Q, Zhang S, Wang M, Yi Q, et al
    Correction: Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Dec 5. doi: 10.1038/s41388-025-03656.
    PubMed    
    
    
    November 2025
15. LIU S, He Y, Ning X, Xu W, et al
    SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
    Oncogene. 2025 Nov 28. doi: 10.1038/s41388-025-03584.
    PubMed     Abstract available
    
    
    October 2025
16. TANG S, Chen K, Zheng F, Fu Z, et al
    High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-kappaB1 pathway in epithelial ovarian cancer.
    Oncogene. 2025 Oct 22. doi: 10.1038/s41388-025-03609.
    PubMed     Abstract available
    
    
    
17. WU L, Wu C, He S, Chen Y, et al
    METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression.
    Oncogene. 2025 Oct 16. doi: 10.1038/s41388-025-03594.
    PubMed     Abstract available
    
    
    September 2025
18. LIU J, Ning J, Wang Y, He X, et al
    FOXA2 sensitizes endometrial carcinoma to progestin-mediated conservative therapy by triggering PR transcriptional activation.
    Oncogene. 2025 Sep 13. doi: 10.1038/s41388-025-03564.
    PubMed     Abstract available
    
    
    
19. HUANG L, Zhu M, Chen M, Ying F, et al
    LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03561.
    PubMed     Abstract available
    
    
    August 2025
20. LABUDA SE, Broaddus RR, Gladden AB
    ARID1A: gene, protein, and function in endometrial cancer.
    Oncogene. 2025 Aug 18. doi: 10.1038/s41388-025-03539.
    PubMed     Abstract available
    
    
    
21. LI Q, Zhang S, Wang M, Yi Q, et al
    Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522.
    PubMed     Abstract available
    
    
    July 2025
22. SHEN C, Cao R, Zhou Q, Zhou T, et al
    LINC00654 promotes ovarian cancer progression by facilitating nuclear export of HuR and stabilizing oncogenic mRNAs.
    Oncogene. 2025 Jul 22. doi: 10.1038/s41388-025-03500.
    PubMed     Abstract available
    
    
    May 2025
23. SONG C, Lin Y, Cai C, Tao K, et al
    LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.
    Oncogene. 2025 May 31. doi: 10.1038/s41388-025-03466.
    PubMed     Abstract available
    
    
    
24. NARAYANA RVL, Gupta R
    Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03448.
    PubMed     Abstract available
    
    
    
25. ZHANG C, Jiang H, Yuan L, Liao Y, et al
    Correction: CircVPRBP inhibits nodal metastasis of cervical cancer by impeding RACK1 O-GlcNAcylation and stability.
    Oncogene. 2025 May 15. doi: 10.1038/s41388-025-03440.
    PubMed    
    
    
    April 2025
26. ZHU Y, Abedini A, Rodriguez GM, McCloskey CW, et al
    Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03387.
    PubMed     Abstract available
    
    
    
27. LI Y, Chen Z, Gao Y, Liu Y, et al
    SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating alpha6 integrin subunit expression.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03386.
    PubMed     Abstract available
    
    
    
28. WAGNER V, Morton M, Dorayappan KDP, Gonzalez A, et al
    Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03382.
    PubMed     Abstract available
    
    
    March 2025
29. ZHAO X, Lai H, Li G, Qin Y, et al
    Rictor orchestrates beta-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer.
    Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03351.
    PubMed     Abstract available
    
    
    
30. WANG J, Yang F, Chen Y, Xing Y, et al
    A positive feedback loop of OTUD1 and c-Jun driven by leptin expedites stemness maintenance in ovarian cancer.
    Oncogene. 2025 Mar 19. doi: 10.1038/s41388-025-03342.
    PubMed     Abstract available
    
    
    
31. ZHAI F, Li Y, Zheng J, Yan C, et al
    SPOP/NOLC1/B4GALT1 signaling axis enhances paclitaxel resistance in endometrial cancer by inducing O-dysglycosylation.
    Oncogene. 2025 Mar 17. doi: 10.1038/s41388-025-03347.
    PubMed     Abstract available
    
    
    
32. FANG D, Chen H, Zhu JY, Wang W, et al
    Editorial Expression of Concern: Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03333.
    PubMed    
    
    
    February 2025
33. XI Q, Kunita A, Ogawa M, Ka M, et al
    Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.
    Oncogene. 2025 Feb 24. doi: 10.1038/s41388-025-03312.
    PubMed     Abstract available
    
    
    
34. STEWART J, Krastev DB, Brough R, Zatreanu D, et al
    PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
    Oncogene. 2025 Feb 12. doi: 10.1038/s41388-024-03265.
    PubMed     Abstract available
    
    
    January 2025
35. DONG P, Xiong Y, Yu J, Chen L, et al
    Editorial Expression of Concern: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
    Oncogene. 2025 Jan 29. doi: 10.1038/s41388-025-03285.
    PubMed    
    
    
    
36. WANG M, Yan Q, Song Y, Zhang Z, et al
    Correction: Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
    Oncogene. 2025 Jan 27. doi: 10.1038/s41388-025-03280.
    PubMed    
    
    
    
37. HAN X, Xia L, Wu Y, Chen X, et al
    m6A-modified circSTX6 as a key regulator of cervical cancer malignancy via SPI1 and IL6/JAK2/STAT3 pathways.
    Oncogene. 2025 Jan 15. doi: 10.1038/s41388-024-03260.
    PubMed     Abstract available
    
    
    December 2024
38. ZHAI X, Shen N, Guo T, Wang J, et al
    SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.
    Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
    PubMed     Abstract available
    
    
    
39. CHIA ML, Bulat F, Gaunt A, Ros S, et al
    Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.
    Oncogene. 2024 Dec 6. doi: 10.1038/s41388-024-03231.
    PubMed     Abstract available
    
    
    
40. DUAN Q, Wang W, Xiong H, Xiao J, et al
    JAK2/ULK1 axis promotes cervical cancer progression by autophagy induction and SRPK1 phosphorylation.
    Oncogene. 2024 Dec 4. doi: 10.1038/s41388-024-03246.
    PubMed     Abstract available
    
    
    October 2024
41. SAKAUE T, Dorayappan KDP, Zingarelli R, Khadraoui W, et al
    Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.
    Oncogene. 2024 Oct 16. doi: 10.1038/s41388-024-03182.
    PubMed     Abstract available
    
    
    
42. SHI J, Zhou R, Wang S, Liu Y, et al
    NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03187.
    PubMed     Abstract available
    
    
    
43. LI Y, Yang H, Li A, Chen B, et al
    CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03188.
    PubMed     Abstract available
    
    
    
44. LIU Y, Li J, Xu J, Long Y, et al
    m(6)A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation.
    Oncogene. 2024 Oct 10. doi: 10.1038/s41388-024-03185.
    PubMed     Abstract available
    
    
    
45. SUN X, Ye G, Li J, Yuan L, et al
    The tumor suppressor Parkin exerts anticancer effects through regulating mitochondrial GAPDH activity.
    Oncogene. 2024;43:3215-3226.
    PubMed     Abstract available
    
    
    September 2024
46. SANG X, Han J, Wang Z, Cai W, et al
    SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways.
    Oncogene. 2024 Sep 21. doi: 10.1038/s41388-024-03173.
    PubMed     Abstract available
    
    
    
47. CHEN J, Shan W, Jia Q, Chen Y, et al
    USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
    Oncogene. 2024 Sep 10. doi: 10.1038/s41388-024-03151.
    PubMed     Abstract available
    
    
    August 2024
48. ONJI H, Tate S, Sakaue T, Fujiwara K, et al
    Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Oncogene. 2024;43:2475-2489.
    PubMed     Abstract available
    
    
    June 2024
49. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
    TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
    Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
    PubMed     Abstract available
    
    
    May 2024
50. PATTERSON MR, Meijers AS, Ryder EL, Wootton LM, et al
    E7-mediated repression of miR-203 promotes LASP1-dependent proliferation in HPV-positive cervical cancer.
    Oncogene. 2024 May 24. doi: 10.1038/s41388-024-03067.
    PubMed     Abstract available
    
    
    
51. ZHANG C, Xu Y, Zhu X, Zhang X, et al
    Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
    Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
    PubMed     Abstract available
    
    
    April 2024
52. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    PubMed     Abstract available
    
    
    
53. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
    Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
    PubMed     Abstract available
    
    
    
54. WEI Y, Chen Z, Li Y, Song K, et al
    The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
    PubMed     Abstract available
    
    
    October 2023
55. EL BABA R, Haidar Ahmad S, Monnien F, Mansar R, et al
    Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells.
    Oncogene. 2023;42:3047-3061.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum